LONDON: OptiBiotix Health plc (AIM: OPTI), a UK-based life sciences company focused on microbiome modulation and healthy sugar alternatives, reported a 35% increase in annual revenue for the year ending Dec. 31, 2024, signaling a strong turnaround bolstered by international expansion and ecommerce growth. Revenue rose to £870,000 from £644,000 in 2023, driven by…
LONDON: Belluscura plc (AIM: BELL), a UK-based medical device innovator specializing in portable oxygen enrichment technology, has launched a strategic funding initiative to strengthen its capital base and support growth. As part of the plan, the company’s wholly owned U.S. subsidiary, Belluscura LLC, has signed a secured convertible loan note agreement to raise up…
LONDON: N4 Pharma plc (AIM: N4P), a UK-based biotechnology company developing its proprietary Nuvec® gene delivery system for advanced cancer and disease therapies, announced its audited financial results for the year ended Dec. 31, 2024. The company’s annual report and notice of its annual general meeting (AGM) have been distributed to shareholders. The AGM…